Biocon Biologics set to reap Biosimilar Insulin Glargine Opportunity in US
Summary : Drugmaker is banking on the ramp-up of interchangeable biosimilar insulin glargine expecting the product to boost the revenue and profit…
Summary : Drugmaker is banking on the ramp-up of interchangeable biosimilar insulin glargine expecting the product to boost the revenue and profit…
Summary : -Biocon Biologics Ltd, said its partner Viatris has won favourable decisions from a US federal court in Sanofi’s challenge over…
Synopsis: Under the terms of this agreement, Tabuk Pharmaceuticals will hold the marketing authorisation for select speciality products of Biocon and be…
Summary: Biocon Pharma has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for…